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Abstract
Background: Ocular melanoma is a rare but often deadly malignancy that arises in the uvea (commonest primary
site), conjunctiva or the orbit. Primary orbital melanoma (POM) is exceedingly rare, with approximately 60 cases
reported to date. Despite recent advances in our understanding of the genetics of primary uveal and conjunctival
melanomas, this information is lacking for POM.
Methods: DNA was extracted from 12 POM tissues, with matched germline DNA (where available). MLPA was
conducted to detect chromosomal alterations and Sanger sequencing used to identify point mutations in candidate
melanoma driver genes (BRAF, NRAS, KRAS, GNA11, GNAQ), and other genes implicated in melanoma prognosis (EIF1AX,
SF3B1). Immunohistochemistry was performed to analyse BAP1 nuclear expression.
Results: MLPA detected copy number alterations in chromosomes 1p, 3, 6 and 8. Sequencing of melanoma driver
genes revealed GNAQ (p.Q209L) mutations in two samples; although it is possible that these samples represent
extraocular spread of an occult uveal melanoma. A recurrent mutation in SF3B1 (p.R625H) was observed in indolent,
but not aggressive, tumours; a mutation in EIF1AX (p.N4S) was detected in one patient with non-aggressive disease.
Conclusions: EIF1AX and SF3B1 mutations appear have a role in determining the clinical course of POM and detection
of these changes could have clinical significance. Further in depth analysis of this rare group using differing ‘omic
technologies will provide novel insights into tumour pathogenesis.
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Background
Ocular melanoma is a rare, generally lethal, malignancy
that can arise in the uveal tract, the conjunctiva, or the
ocular adnexa (eyelid or orbit). Orbital melanoma occurs
either as primary disease, as secondary disease (local in-
vasion from an ocular or sinonasal primary tumour), or
as a metastasis from the contralateral eye or from the
skin. Melanoma accounts for 5–20% of metastatic and
secondary orbital malignancies, but only a very small
proportion of primary orbital neoplasia [1–3]. Primary
orbital melanoma (POM) is extremely rare, with ap-
proximately 60 cases reported to date. It is possible that
POM arise from melanocytic cells lining the leptomenin-
ges or ciliary nerves, or from ectopic intraorbital nests
of melanocytes [4]. POM can occur de novo, but it is
sometimes reported in association with pigmentary
changes of the periocular tissues – such as naevus of
Ota, blue cellular naevus or oculo-dermal melanosis [5].
The prognosis of POM appears to be quite variable.
Generally, the disease is considered to have a very poor
prognosis, but there appears to be a subset of patients
who have long-survival [6, 7].
The genetic aberrations that drive cutaneous melan-
oma (CM) and uveal melanoma (UM) are well-described
and quite distinct from each other. Mutations in the
RAS pathway are found in > 75% of CM and have also
been described in conjunctival melanoma, whereas mu-
tations in GNAQ and GNA11 are found in ~ 85% of UM
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[8, 9]. Several genes have also recently been implicated
in UM prognosis, such as BAP1, SF3B1 and EIF1AX.
There are no data, however, describing the genetic alter-
ations found in POM. In this study, we examined POM
for alterations in candidate melanoma driver genes
(BRAF, NRAS, KRAS, GNA11, GNAQ) and genes impli-
cated in UM prognosis (EIF1AX, SF3B1, BAP1).
Methods
This study received ethics approval from Moorfields Eye
Hospital Biobank ethics board (15/SW/0104). Informed,
written consent was obtained from patients and research
adhered to the tenets of the Declaration of Helsinki.
Twelve tumour DNA samples from 11 patients were in-
cluded in the study; the demographics and clinical
course (including disease presentation, occurrence of
metastasis and overall survival) of the patients has been
previously published but is also summarised in Table 1
[7]. Prognosis was defined as poor (survival of < 6
months with or without metastasis), intermediate (sur-
vival > 6 months with local or systemic spread of disease)
or good (survival > 6months without spread; or very late
recurrence of disease (> 10 years)).
DNA extraction
Tumour DNA was extracted from surgical samples as
previously described [10]. Germline DNA was extracted
from peripheral blood using standard phenol-based
method.
MLPA
MLPA was undertaken using the SALSA MLPA
P027-C1 kit (MRC Holland, The Netherlands) according
to manufacturer’s instructions and previously published
methods [10], to detect copy number alterations of chro-
mosomes 1p, 3, 6 and 8. Classification of chromosomes
was based on the dosage quotients generated and ≥ 75%
probes on a particular chromosome being classified as
Table 1 Summary of clinical characteristics of 11 patients with primary orbital melanoma. “RT” denotes fractionated external beam
radiotherapy. † indicates a deceased patient
Case
no.
Gender Age
at
onset
(years)
Side Primary treatment
of orbital
disease
Orbital
progression
Time orbital
treatment to
orbital
recurrence
(months)
Systemic
progression
Time orbit
to systemic
disease
(months)
Systemic
therapy
Survival
(months)
Notes
1 F 81 R Debulking N – Y 0 3† Too unwell for
adjuvant
radiotherapy
2 M 40 L Exenteration N – Y 0 4† Too unwell for
adjuvant
radiotherapy
4 F 58 L Exenteration Unknown – Unknown – 25 Patient declined
adjuvant
radiotherapy &
active follow up
5 M 45 L Debulking + RT Y 6 N – 37 Exenteration
after orbital
progression
6 F 84 R Exenteration + RT N – Y 12 Palliative RT
for bone
metastases
18† Conjunctival
melanosis
8 M 45 L Debulking + RT Y 7 Y 45 Liver resection 91 Nevus of Ota
Exenteration
after orbital
progression
9 F 47 L Debulking + RT Y 161 Y 168 Nil active 174† Conjunctival
nevus
Late
exenteration
10 M 46 R Debulking +RT N – N – 26
11 F 43 L Debulking + RT N – N – 188 West African
12 F 70 L Debulking +RT N – N – 22
13 M 55 R Debulking + RT Y 2 Y 5 Immunotherapy 35 Immunotherapy
for progressive
systemic and
orbital disease
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loss, normal or gain as previously described [11]. Chro-
mosomes were considered ‘unclassified’ when the cri-
teria could not be met.
Sanger sequencing
PCR was performed using custom primer sequences to
target regions (Table 2) using PCR Master Mix 2X,
ThermoFisher Scientific UK (cycle conditions available
upon request). Sanger sequencing was performed using
BigDye Terminator v3.1 on ABI3730 using a standard
protocol (both Applied Biosystems, UK). Sequence data
was analysed on Seqman Pro (DNASTAR, USA). Identi-
fied changes were validated in a second PCR and se-
quencing reaction. Validated mutations were assayed in
germline genomic DNA from the patient, to confirm
that they were a somatic mutation.
BAP1 immunohistochemistry
BAP1 protein expression was examined in 4 μm sections
of each POM case using a mouse anti-BAP1 antibody
(sc-28,383, Santa Cruz, Insight Biotechnology Ltd.,
Middlesex, UK) and the DAKO Envision FLEX Kit, ac-
cording to previously published methods [12]. POM
were classified as either BAP1 positive or BAP1 negative
according to whether the tumour cells displayed nuclear
staining or not, respectively.
Results
Copy number changes in chromosomes 6 and 8 are
frequently observed in POM
MLPA was performed to investigate chromosomal
changes within POM. Copy number alterations were ob-
tained for 7/11 tumour samples (Table 3). Four tumours
were reported as disomy 3 and three cases had unclassi-
fiable chromosome 3 status. The most frequent change
was gain of chromosome 6p, in 5/7 cases. Polysomy 8q
was reported in four cases; gain of chromosome 1p was
also observed (2/7 cases). It was not possible to correlate
chromosomal alterations with outcome because of the
small number of patients for whom data were available.
Analysis of driver mutations in POM
Sequencing of mutation hotspots in five melanoma
driver genes (BRAF, NRAS, KRAS, GNAQ, GNA11) did
not reveal any changes in 9/11 patients. In two patients
(numbers 4 and 5), a change in GNAQ was found:
c.A626T, p.Q209L (Fig. 1a). GNAQ mutations account
for approximately 50% of UM driver changes, and
p.Q209L is found in 33% of GNAQ mutant tumours
[13]. It was considered, therefore, whether these two
samples could represent an extraocular manifestation of
a primary UM, with an occult uveal source. Review of
the available imaging did not reveal any possible uveal
source. In light of this, the histology slides were
re-reviewed by a second expert pathologist (PL, blinded
Table 2 Regions of interest assayed and primer sequences used. The commonly reported mutations in the exons of interest were
taken from individual gene reports on COSMIC database [13]
Gene Exon Forward primer Reverse primer Previously reported mutations Implicated in
BRAF 11 CTGTTTGGCTTGACTTGAC CATATCCTATTATGACTTG Minor mutation hotspots at
codons 466 and 469
Driver mutation,
cutaneous melanoma
15 CTGATAGGAAAATGAGAT CAGCAGCATCTCAGGGCC p.V600E
NRAS 2 GTGGCTCGCCAATTAAC CCGACAAGTGAGAGAC Mutation hotspots at codons
12 and 13
Driver mutation,
cutaneous melanoma
3 GCATTGCATTCCCTGTGG GAACACAAAGATCATCC p.Q61R, p.Q61L
KRAS 2 GATAGTGTATTAACC AACCTTTATCTGTATC Mutation hotspots at codons
12 and 13
Driver mutation,
cutaneous melanoma
3 GTGCACTGTAATAATCT AATTACTCCTTAATGTC p.Q61R, p.Q61H
GNAQ 4 CTTTCCGTAGACAGCTTTG GTACTCAAGGCATAAAAG p. R183Q Driver mutation,
uveal melanoma
5 GCTATATTTATGTTGAC CTATCATTTACTTGTATC p.Q209L, p.Q209R, p.Q209P
GNA11 4 GCAGCCGGCCTGAGCA ACACACACTGAGGATG p. R183C Driver mutation,
uveal melanoma
5 GCCAGGTGGCTGAGT GCAGGGCCTTACTGG p.Q209L, p.Q209P
SF3B1 14 GGCCGAGAGATCATTTCTAAT AAGAAGGGCAATAAAGAAGGA Mutation hotspot at codon 625,
and multiple other hotspots
Prognosticating mutation
in uveal melanoma, possible
driver mutation
EIF1AX 1 GCCACGCCTGCGTCATAAAG CGAGCTCAGAGTCGCGTGTG Mutation hotspots at
codons 2,3,4,6
Prognosticating mutation in
uveal melanoma, possible
driver mutation
2 AAAGGAAATTCCAAGAAGGGTAGGG TAATCGTGCCACCACACTTCACC Mutation hotspots at
codons 13, 15
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to genetic findings). It was observed that patient 4 had
some small regions of increased pigmentation in the
choroid that might represent a uveal source of the
tumour, although it was felt more likely that these were
insignificant findings given the benign appearance and
size of the lesions (Fig. 2). In the case of patient 5, the
exenteration sample was not available for histological
analysis and, so, although there was no evidence of chor-
oidal involvement in the samples examined, it remains
impossible to fully exclude an occult uveal source.
Identification of a recurrent change in SF3B1
Sequencing of exon 14 of SF3B1 revealed that four pa-
tients (cases 4, 9, 11, 12) harboured the same mutation;
c.G1874A, p.R625H (Fig. 1b). One patient (case 10) was
found to harbour a change in exon 1 of EIF1AX; c.A11T,
p.N4S (Fig. 1c). These changes were not present in the
germline DNA of the patients.
It was noted that the patients harbouring the recurrent
SF3B1 mutation all had highly favourable prognosis
(Table 4). The mean survival to-date of those patients
harbouring the SF3B1 mutation is 104.8 months (range
= 22–188 months), whilst the mean survival of patients
without the SF3B1 mutation is 29.8 months (range = 3–
91months). It is not possible, however, to assess the sig-
nificance of these differences due to the small sample
size. Furthermore, it should be noted that of the seven
patients with systemic and/or orbital progression of dis-
ease, only one carried the SF3B1 mutation – and this pa-
tient remained without disease progression for over 13
years prior to sudden recurrence, deterioration and
death. The SF3B1 mutation was found in both the first
tumour biopsy sample (disease which remained quies-
cent for 13 years) and the recurrent tumour sample.
BAP1 immunohistochemistry
BAP1 IHC was possible in 10 cases, a single case had no
remaining available tumour material. Nuclear BAP1
(nBAP1) expression was noted in the tumour cells in
eight cases and was absent in two (Fig. 3). Of the two
nBAP1 negative cases, one showed disomy of chromo-
some 3 and the presence of SF3B1 and GNAQ muta-
tions, whilst in the second case MLPA had not yielded
any results and no mutations were detected.
Discussion
In this study we examined the largest reported clinical
series of POM for mutations implicated in melanoma,
giving the first report of genetic alterations in this rare
tumour. It was demonstrated that POM appears to be
genetically distinct to CM, but shares some overlapping
features with UM; however, a distinct driver mutation
might exist in at least some cases of POM. Furthermore,
mutations in SF3B1 and EIF1AX might influence prog-
nosis. POM is an extremely rare tumour, with approxi-
mately 60 cases reported to-date in the literature. One
striking feature is the highly variable prognosis – whilst
most reported cases have a dismal prognosis, a subset of
patients appear to follow a relatively benign course [6,
7]. This feature was certainly observed in the patient co-
hort used in this study – some patients had aggressive
primary disease with widespread systemic involvement
and rapid deterioration; whereas other patients survived
for more than a decade [7].
POM were not associated with monosomy 3 in the
small number of tested samples, which is a frequent
chromosomal alteration in UM associated with poor
prognosis [14]. In addition, although polysomy 8q was
observed in 4/7 POM in this cohort, all were associated
with patients who had a good prognosis, which again is
Table 3 MLPA, gene sequencing and BAP1 IHC in eleven primary orbital melanoma cases. The case number refers to the clinical
histories previously published [7]. G gain, U unclassified, N normal copy normal, L loss; − reference sequence, + heterozygous
mutation observed
Case ID BAP1
IHC
MLPA result - chromosome SF3B1
(R625H)
EIF1AX
(N4S)
GNAQ
(Q209L)1p 3 6p 6q 8p 8q
1 Positive G U G N N G – – –
2 Positive MLPA QC fail – – –
4 Negative N N G N N G + – +
5 Positive MLPA QC fail – – +
6 NA N N N N N N – – –
8 Positive N U G N N N – – –
9 Positive G N G L L G + – –
10 Positive N N G N N G – + –
11 Positive U U U G G N + – –
12 Positive MLPA QC fail + – –
13 Negative MLPA QC fail – – –
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contrary to its association with a poor outcome in UM.
These data would suggest that chromosomal alterations
in POM do not follow a similar pattern to that observed
in UM, although testing of more cases will be important.
Similarly, loss of nBAP1, which is associated with a poor
prognosis and monosomy of chromosome 3 in UM [12,
15, 16] was noted in only two cases and was neither as-
sociated with a poor outcome nor with monosomy of
chromosome 3.
Mutations in genes of the MAPK pathway are known
to drive the majority of cases of CM. Mutations in BRAF
account for the majority of driver mutations (up to 60%)
[17]. However, mutations in NRAS and KRAS are also
relatively frequent (13–25 and 2%, respectively) [18].
Screening for mutations in these genes did not, however,
reveal any changes in our POM cohort. Mutations in
two Gq alpha sub-unit genes, which interact indirectly
with the MAPK pathway, are found frequently in UM:
GNAQ (~ 45%) and GNA11 (~ 35%) [19, 20]. In our co-
hort, two cases (patients 4 and 5) were found to carry a
heterozygous mutation in GNAQ (p.Q209L). This
change is the most frequently observed change in GNAQ
mutant UM, occurring in one third of such cases [21].
This dominant-negative mutation alters the catalytic
(GTPase) domain of GNAQ and results in a constitu-
tively active protein [22]. Expression of GNAQ p.Q209L
in mice resulted in malignant transformation of melano-
cytes and increased signalling through the MAPK path-
way [21]. It is often speculated whether POM cases are
true primary disease, or whether an occult uveal source
might be present. It was considered necessary, therefore,
to assess whether these two cases could be occult uveal
tumours, given the frequency of GNAQ p.Q209L in UM.
The imaging of both cases was reviewed, and a uveal
source could not be discerned. The tumour histology of
the cases was re-reviewed by an expert pathologist,
Fig. 2 a H&E staining of serial slices of exenteration specimen
revealed several small regions of increased choroidal melanosis
in case 4 (arrowed). b Representative image of region with
increased pigmentation, showing that the pigmented cells were
not malignant in appearance
Fig. 1 Point mutations identified in tumour tissue of primary orbital
melanoma. a Two cases (patients 4 and 5) harboured a heterozygous
mutation in GNAQ (c.A626T, p.Q209L). b A recurrent heterozygous
mutation in SF3B1 (c.G1874A, p.R625H) was identified in four patients
with favourable prognoses (cases 4, 9, 11, 12). c One patient, case 10,
carried a heterozygous change in EIF1AX (c.A11T, p.N4S)
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Table 4 Correlation between prognosis in patients harbouring SF3B1 and EIF1AX changes versus wildtype patients. Deceased
patients indicated by †; survival correct to January 2018. The two patients highlighted in grey might represent secondary orbital
melanoma with an occult uveal origin
Case no. Prognosis group Orbital progression Systemic progression Survival (months) SF3B1 p.R625H EIF1AX p.N4S
1 Poor No Yes 3†
2 No Yes 4†
13 Intermediate Yes Yes 25
5 Yes No 37
6 No Yes 18†
8 Yes Yes 91
9 Good Yes (after 13 years) Yes (after 13 years) 174† YES
10 No No 26 YES
11 No No 188 YES
12 No No 22 YES
4 Unknown Unknown 35 YES
Fig. 3 Representative images of BAP1 immunohistochemistry. a H&E and nuclear BAP1 (nBAP1) negative tumour (Case ID 13), with normal
staining found in admixed lymphocytes. b H&E and nBAP1 positive tumour (Case ID 12). Insets show nBAP1 staining at ×40 magnification
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without knowledge of the genetic findings. In one case
harbouring the GNAQ change, there was evidence of
very minor choroidal pigmentary changes which could
represent a possible uveal source; in the other case, there
was insufficient biopsy material to fully exclude a uveal
source. It is possible, therefore, that these two cases
might indeed have an occult uveal source. It is also
plausible, however, that these are POM that share com-
mon genetic features with UM. Mutations in other G
protein genes, such as CYSLTR2 and PLCB4 have been
reported in a small number of UM patients and these
could be sequenced in our cohort to extend the study
further [23, 24].
Next, it was considered whether mutations in
SF3B1 or EIF1AX contributed to the pathogenesis of
disease and/or variable prognosis seen within our co-
hort. Mutually exclusive changes in both genes were
found (which might associate with good prognosis),
highlighting another feature that overlaps with the
genetic landscape of UM. Sequencing of exon 14 of
SF3B1 revealed a recurrent heterozygous mutation
(c.G1874A, p.R625H) in four patients – cases 4, 9, 11
and 12. It was noted that all four of these patients
had a favourable outcome, with a mean survival
to-date of 104.8 months (22–188 months). Three of
these patients have not had any local or systemic pro-
gression or recurrence of disease. One patient – case
9 – harbouring the SF3B1 mutation had systemic pro-
gression and has since died, however, this was after a
remarkable disease-free period of 13 years. The pres-
ence of the SF3B1 mutation was confirmed in both
the primary and recurrent tumour of this individual.
In contrast, no patients with poor survival, or early
local/systemic progression, carried the SF3B1 change.
This would suggest that the observed mutation in
SF3B1 confers a favourable prognosis in POM.
SF3B1 encodes splicing factor 3b, subunit 1 protein,
which is a component of the splicing factor 3b protein
complex. This complex is part of the spliceosome, the
macromolecular structure responsible for transcriptional
mRNA processing. Mutations in SF3B1 have been impli-
cated as a common driver mutation in myelodysplatic
syndromes (MDS), myelofibrosis and chronic myeloid
leukaemia [25, 26]. In MDS, SF3B1 mutations have been
associated with favourable overall survival and a lower
likelihood of transformation into acute leukaemia [27,
28]. More recently, mutations in SF3B1 (particularly
at codon 625) have been identified in various pigmen-
ted tumours, including UM [29], mucosal melanoma
[30], leptomeningeal melanoma [31] and blue
naevi-like cutaneous melanoma [32]. They are, how-
ever, rare in CM [33, 34]. As with MDS, SF3B1 muta-
tions confer a favourable prognosis in UM, with
lower age of onset and concurrent disomy 3 [35].
However, it should be noted that SF3B1 mutant UM
are reported to give rise to late metastasis (median
8.2 years after initial diagnosis) [36]. Furthermore, The
Cancer Genome Atlas project reported that UM cases
with SF3B1 mutations have an intermediate prognosis
[9]. One of our patients harbouring the change (case
9) did indeed have late onset metastasis to the brain
(13 years after diagnosis). It is also interesting to note
that secondary melanoma within the orbit was noted
to have frequent late recurrence, and the incidence of
SF3B1 in these tumours could be studied [37].
One patient, case 10, was found to harbour a het-
erozygous mutation in exon 1 of EIF1AX (c.A11T,
p.N4S). This patient also had a highly favourable
prognosis. EIF1AX, located on the X chromosome,
encodes the eukaryotic translation initiation factor 1A
protein. This factor is essential in the initiation phase
of translation, through interaction with tRNA and the
ribosome [38]. Mutations in exon 1 or 2 of this gene
have been frequently reported in UM [39], but also
rarer melanoma types including blue-nevus associated
melanoma and leptomeningeal melanoma [33, 34].
EIF1AX mutations are associated with good prognosis
disomy 3 UM, and usually occur in non-metastatic
cases [39–41]. This is in agreement with the patient
reported here, who displayed all of these features
to-date with follow up of over 2 years. It is highly
plausible, therefore, that mutations in EIF1AX also
correspond to good prognosis in POM.
It must be considered whether the changes seen in
SF3B1 and EIF1AX are the driver mutation of POM, or
a secondary change in the tumour. It is thought that
mutations in SF3B1 arise as a second genetic change in
UM and blue nevus-like melanoma, after initial muta-
tion in GNAQ or GNA11; however, SF3B1 changes can
be driver mutations in MDS [25, 34]. Indeed, in UM,
mutations in either gene (SF3B1 or EIF1AX) are almost
never seen in the absence of a GNAQ or GNA11 muta-
tion [13]. Whole exome or whole genome sequencing
of these tumours will be necessary to elucidate the full
spectrum of genetic mutations in POM. A further con-
sideration is the role of underlying precursor or prema-
lignant lesions in the genetic aetiology of POM. The
tumour can arise following malignant transformation of
pigmentary changes of the periocular tissues – such as
naevus of Ota, blue cellular naevus or oculo-dermal
melanosis [5]. This was the case in three individuals
studied here (Cases 6, 8 and 9; in addition, minor
increased choroidal pigmentation was observed on
re-examination of Case 4. It would be interesting to
study the genetic aberrations in the premalignant
tissue, as this might shed light on the temporal occur-
rence of sequential mutations and their role in
pathogenesis.
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Conclusions
In summary, we have provided the first genetic insights
into POM. We have shown that – in contrast to CM
and UM – mutations in the tested MAPK pathway genes
or Gq alpha subunit genes are not implicated in the ma-
jority of POM. Furthermore, we have shown that muta-
tions in either SF3B1 or EIF1AX are likely to be
associated with a favourable prognosis in POM cases.
Testing for these changes in the clinical setting might
allow better prognostication for patients. However, it is
possible that SF3B1 mutations are associated with late
recurrence of disease, and so long-term follow-up and
high index of suspicion should be maintained in all cases
of orbital melanoma. Additional ‘omic technologies,
such as whole genome sequencing, should be used to ex-
plore whether there are other driver mutations involved
in the development of these rare tumours.
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